Rexulti Dosage for Depression: Why 2 mg Is the Usual Target

When an antidepressant helps but doesn’t finish the job, adding Rexulti (brexpiprazole) can sound like turning up a dial until depression lifts. The trial data describe a dial with a sweet spot, and past 2 mg, side effects climb faster than benefit.

Brexpiprazole’s effect may come from partly activating dopamine D2 and serotonin 5-HT1A receptors while blocking serotonin 5-HT2A receptors, according to the Rexulti prescribing information. It also lingers in the body. Its half-life is about 91 hours, so each dose change takes 10 to 12 days to reach steady levels.

The add-on evidence is solid. In a phase 3 trial of 2 mg, adding brexpiprazole to an antidepressant lowered depression scores by 8.4 points on the MADRS scale versus 5.2 with placebo over 6 weeks. A 2019 pooled analysis of four trials with 1,853 people found a modest but statistically significant benefit at 2 to 3 mg. The results are real, and the evidence holds up across studies.

But a target dose on the label still has to fit the person taking it, and at Siggy we believe an add-on medication deserves the same close follow-up as the antidepressant it supports. This guide covers the standard schedule, what each dose did in trials, the side effects that rise with dose, and the factors that move your dose up or down. Where you land between 0.5 and 3 mg depends on response, side effects, and your other medications, not on a fixed ladder.

What This Page Covers

• The Standard Rexulti Schedule for Depression
• What the Trials Show at Each Dose
• Why 2 mg Is the Usual Target
• Side Effects That Rise With Dose
• What Can Lower Your Dose
• Missed Doses and Safety Checks

The Standard Rexulti Schedule for Depression

For major depressive disorder, Rexulti is approved only as an add-on to an antidepressant in adults. The label’s dosing section lays out the steps:

• Start at 0.5 mg or 1 mg once daily.
• Move to 1 mg once daily.
• Move to the 2 mg target, with each increase at weekly intervals based on response and tolerability.
• Don’t exceed 3 mg a day.

You take it once a day, with or without food. Tablets come in 0.25, 0.5, 1, 2, 3, and 4 mg strengths, so small adjustments are possible. The label also asks prescribers to reassess periodically whether you still need it and at what dose.

What the Trials Show at Each Dose

Two 6-week trials tested fixed doses added to an antidepressant, and the label’s trial data report the results by dose alongside side effects from the same studies.

Dose	Extra MADRS Improvement vs Placebo	Akathisia	Average Weight Change at 6 Weeks
Placebo	Reference	2%	+0.3 kg
1 mg	1.3 points, not significant	4%	+1.3 kg
2 mg	3.2 points	7%	+1.6 kg
3 mg	2.0 points	14%	+1.6 kg

The 2 mg result came from one trial and the 1 mg and 3 mg results from another, so the doses weren’t compared head to head. Each trial lasted 6 weeks, and the pooled analysis listed the lack of an active comparator drug as a limitation. The published trial report for 1 mg and 3 mg shows the same pattern: 3 mg separated from placebo, while 1 mg fell just short of significance.

Why 2 mg Is the Usual Target

The strongest case for 2 mg comes from looking across all the trials at once. A 2019 dose-subgroup meta-analysis of nine trials with 3,391 people found that doses of 2 mg or less were tied to better response rates than higher doses. Only the lower-dose group beat placebo on remission and depression scores at 6 weeks, though the gap between dose groups on those two measures wasn’t statistically significant.

The side effect picture pointed the same way. Compared with placebo, doses above 2 mg roughly quadrupled the risk of akathisia while lower doses about doubled it, and only the higher doses raised the risk of sleepiness. The authors concluded that 2 mg or less offered the better balance of benefit and risk.

That doesn’t rule out 3 mg. The label allows it, and it beat placebo in its own trial. The label ties every increase to response and tolerability, so moving past 2 mg is a judgment call rather than an automatic next step. Doses below 2 mg have a role too, as titration steps and, for some people, such as poor metabolizers, as the actual target.

Side Effects That Rise With Dose

Akathisia is the side effect most tied to dose. It’s a form of inner restlessness that can make it hard to sit still. In the label’s pooled depression trials, both akathisia and restlessness increased as the dose went up.

Weight tends to rise more with time than with dose. Over 6 weeks, average gain was 1.3 to 1.6 kg across doses, versus 0.3 kg on placebo. In long-term open-label studies, average gain reached 2.9 kg at 26 weeks and 3.1 kg at 52 weeks. Thirty percent of people gained at least 7% of their body weight, and 4% stopped because of weight gain.

In the 6-week trials, sleepiness affected 4% of people on Rexulti versus 1% on placebo, and 3% stopped because of side effects versus 1% on placebo. The label also calls for checks of weight, fasting glucose, and lipids before or soon after starting and periodically afterward. It lists rarer risks too, including tardive dyskinesia, compulsive urges such as gambling, and dizziness or fainting when standing up.

What Can Lower Your Dose

Several factors raise brexpiprazole levels, and the label’s modification table adjusts for them.

Factor	Rexulti Dose Adjustment
CYP2D6 poor metabolizer	Half the usual dose
Strong CYP3A4 inhibitor	Half the usual dose
Strong CYP2D6 inhibitor, in depression	No change
CYP2D6 plus CYP3A4 inhibitors, or poor metabolizer plus CYP3A4 inhibitor	A quarter of the usual dose
Strong CYP3A4 inducer	Double, over 1 to 2 weeks
Moderate to severe liver impairment, or CrCl under 60	2 mg maximum

The label estimates that about 8% of White people and 3% to 8% of Black people are CYP2D6 poor metabolizers. The FDA’s drug interaction table lists clarithromycin and itraconazole among strong CYP3A4 inhibitors, and rifampin and St. John’s wort among strong inducers.

The row that matters most for depression is the exception. Fluoxetine (Prozac) and paroxetine (Paxil) strongly inhibit CYP2D6, but the depression trials didn’t adjust brexpiprazole for them, so the label says no change is needed. If an interacting drug is stopped, the dose goes back to its original level, and after a strong inducer is stopped, it comes down over 1 to 2 weeks. For how dose changes can be handled without losing track of what’s working, see our guide to adjusting an antidepressant dose without losing continuity.

Missed Doses and Safety Checks

If you miss a dose, MedlinePlus drug guidance advises taking it as soon as you remember, unless it’s almost time for the next one. In that case, skip it and don’t double up.

Like antidepressants, Rexulti carries a boxed warning about suicidal thoughts and behaviors in people 24 and younger, especially early in treatment and after dose changes. A second boxed warning covers a higher risk of death in older adults with dementia-related psychosis. Tell your prescriber promptly about:

• Restlessness that makes it hard to sit still
• New urges to gamble, shop, eat, or have sex that feel hard to control
• Movements you can’t control, especially of the face or tongue
• Dizziness or fainting when you stand up

If you have thoughts of harming yourself or a sudden change in mood or behavior, call 911 or call or text 988 right away.

With an add-on like Rexulti, the side effect most tied to dose, restlessness, can be easy to dismiss as anxiety or a rough week, and a dose decision can hinge on naming it early.

Because Rexulti’s side effects rise with dose, a simple record of restlessness, sleep, weight, and mood gives your prescriber something concrete to weigh before the next dose decision.

Rexulti’s range runs from 0.5 to 3 mg, and the evidence clusters around 2 mg, with your response, side effects, genes, and other medications deciding where you actually land. For a wider view of next steps when depression doesn’t lift, see our guide to treatment-resistant depression options.

Ready to take control of your mental health? Start your anonymous intake with Siggy and get your plan reviewed by a licensed prescriber.

This article is for education only and isn’t a substitute for personal medical advice. Talk with your own clinician before starting, changing, or stopping any medication.